Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Immatics Plans FDA Submission for Anzu-Cel in 2027

18 August 2026 · By · Wire by Fusion42

Published

18 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at precisionmedicineonline.com →

◆ Verified

Fusion42 · 18 August 2026 · Fusion42 review

Immatics announced plans to submit its cell therapy Anzu-Cel for FDA approval in 2027, targeting precision oncology treatment advancements.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech venture will face new US market opportunities with FDA review timelines crystallising for Anzu-Cel. Prepare regulatory and commercial strategies now for this upcoming cell therapy approval pathway.

◆ Coverage

1 source · 18 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-submissioncell-therapyprecision-oncologyclinical-trialsbiotech